Pfizer drug trial victims start to receive compensation

By Admin
Share
People in Nigeria have started to receive long-awaited compensation payments from Pfizer after a botched drug trial. Eleven children died and dozens mo...

People in Nigeria have started to receive long-awaited compensation payments from Pfizer after a botched drug trial.

Eleven children died and dozens more developed disabilities during a 1996 trial of an experimental drug treatment for meningitis.

Four families have received $175,000 in the first batch of payouts after they obtained DNA evidence their children’s deaths were caused from the trial.

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

However, the company has been criticised for only compensating four families in the initial round of payouts despite 200 children taking part in the trial.

The money for the compensation has come from a $35 million fund created as part of the settlement between Pfizer and the northern Kano state in Nigeria where the trial took place.

As part of the settlement Pfizer has also agreed to fund health projects in the Kano region.

However, the company is still insistent the deaths were caused by meningitis and not the drugs it was testing.

In a statement the pharmaceutical company said: “This is the first step in a multi-phase review process by which the independent board of trustees that manages the fund will deliver payment to all other qualified claimants.

“We thank them for their commitment and dedication to seeing this process through in the most timely and transparent way possible.”

Share

Featured Articles

How Huawei's Digital Solutions are Transforming Healthcare

Offering network, cloud, and AI solutions, Huawei is able to help healthcare providers deliver better outcomes for patients

2024 Nestlé Nutrition Symposium Explored Food & Health

Nestlé manufactures 4.5m KitKats every day, but the food giant is also focused on advancing food nutrition, as explored at the 2024 International Symposium

Thirona’s AI Tech is Creating Individualised Patient Care

Eva van Rikxoort, CEO and Founder of Thirona, tells us how AI technology is advancing lung imaging and bringing more individualised treatment to patients

AstraZeneca’s Discovery Centre, Constructed by Mace Group

Technology & AI

NeoGenomics: Data in Oncology Testing & Diagnostics

AI & ML

Samsung’s New Health Software Development Kit Suite

Digital Healthcare